

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **1994-01-19** | Period of Report: **1994-01-19**
SEC Accession No. **000009892-94-00002**

([HTML Version](#) on [secdatabase.com](#))

FILER

BARD C R INC /NJ/

CIK: **9892** | IRS No.: **221454160** | State of Incorpor.: **NJ** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **001-06926** | Film No.: **94501853**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
730 CENTRAL AVENUE
MURRAY HILL NJ 07974

Business Address
730 CENTRAL AVE
MURRAY HILL NJ 07974
9082778000

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report: January 19, 1994

C. R. Bard, Inc.
(Exact name of registrant as
specified in its charter)

New Jersey
(State of
Incorporation)

1-6926
Commission File Number

22-1454160
IRS Employer
Identification No.

730 Central Avenue, Murray Hill, New Jersey
(Address of principal executive offices)

07974
(Zip Code)

(908) 277-8000
(Registrant's telephone number)

Item 5. Other Events

In a news release dated January 19, 1994, C. R. Bard, Inc. announced that the Food and Drug Administration has determined that provisions of the Applications Integrity Policy (AIP) should be applied to its USCI division. The news release, issued by the Company on January 19, 1994, is incorporated herein by reference, and is attached hereto as Exhibit 1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

C. R. BARD, INC.
(Registrant)

By: William C. Bopp /s/
William C. Bopp
Senior Vice President
and Chief Financial Officer

Dated: January 19, 1994

Exhibit 1

C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

News Release

Contact: William C. Bopp
Senior Vice President & CFO
(908) 277-8221

FDA APPLIES AIP TO PENDING APPLICATIONS OF BARD'S USCI DIVISION

MURRAY HILL, NJ - January 19, 1994 - C.R. Bard, Inc. announced today that the Food and Drug Administration (FDA) has determined that provisions of the Applications Integrity Policy (AIP) should be applied to its USCI division.

Consequently, FDA has suspended its review of pre-market applications that have been submitted by the USCI division and which are currently pending clearance by the Center for Devices and Radiological Health. Based upon audits to be conducted by the company, the FDA will assess the validity of data and information in USCI's pending pre-market applications.

The company is in continuing discussions in certain related areas raised by FDA to finally conclude this matter.

C.R. Bard, Inc., headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of health care products.